James Thomas Coates, Ph.D. and his team at Decisive Point specialize in helping biotech startups realize direct routes to millions of dollars in federal funding from a host of not-so-intuitive federal institutions and helping them optimize funding from more obvious federal agencies such as DARPA and the NIH. On Business of Biotech, Dr. Coates shares strategies and resources for tapping into biopharma capital that's ripe for the taking.
Article |
By Karl Charbonneau and Adam Hopper,Cambrex
Regular assessments of a partnership’s value in terms of supply chain, operational efficiency, data analysis, and more can optimize and extend the product life cycle.
Cell line development involves multiple processes. Large numbers of clones are screened and selected on the basis of productivity and stability. An established platform for the rapid titer of antibody clones can enable quick selection of high-producing clones.
Challenges exist when developing biologic drugs to be efficacious but safe. Novel analytical techniques, such as surface plasmon resonance, can help circumvent these issues and optimize development.
A pharmaceutical company was looking to partner with a CMO with commercial manufacturing capabilities, large-scale assets, multinational sites and exemplary quality systems/U.S. FDA track records.
Dr. Noel Smith, Ph.D., head of immunology at Lonza, answers attendee questions from a webinar about how to overcome challenges with immunogenicity and immunotoxicity assessments in drug development.
While numerous companies succeed in developing promising ADCs, manufacturing such complex and highly potent treatments presents unique challenges. Get an insider look at how these treatments make it from development to commercialization.
